ClinicalTrials.gg
TerminatedNCT00579020Updated Dec 5, 2012

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

A Phase 2 interventional study of Moxifloxacin/dexamethasone phosphate ophthalmic solution and Moxifloxacin ophthalmic solution 0.5% in Corneal Infiltrates, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-12-05.

Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment

Why this study was terminated
Management decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Corneal Diseases with a site in United States — 12 open to participants now, 13 under way, 3 of them phase 3. Corneal Diseases · United States.

Enrollment
19th of 54
144 · median 79
Started
2007
with 7 others
Phase 2
6 of 76
1 open now
Registered
17th of 76
by date

Among the 76 studies in Corneal Diseases with a site in United States, this one is the 19th largest by enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2007, is one of 6 in phase 2, and was the 17th registered.

Corneal Diseases

219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.

Browse Corneal Diseases studies →

Open to participants now

12 of the 76 studies in Corneal Diseases with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Corneal Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.

03

Conditions studied

  • Corneal Infiltrates

Keywords

  • cornea
  • inflammation
  • blepharitis
  • lid infection
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of marginal corneal infiltrates of size equal to or less than 1.5mm in diameter, with mild, moderate or severe bulbar conjunctival injection in at least one eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Age related.
  • Other protocol-defined exclusion criteria may apply.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Moxidex

    Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days

    Drug: Moxifloxacin/dexamethasone phosphate ophthalmic solution

  • Active comparator
    Moxifloxacin

    Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days

    Drug: Moxifloxacin ophthalmic solution 0.5%

  • Active comparator
    Dexamethasone

    Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days

    Drug: Dexamethasone phosphate solution, 0.1%

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with resolution of all corneal stromal infiltrate(s) in study eye at Test of Cure (TOC) Visit (Day 10)

    Time frame: Day 10

Secondary outcomes

  1. Percentage of patients with eradication of pre-therapy pathogens from the lid of the study eye at TOC Visit (Day 10)

    Time frame: Day 10

07

Study locations

1 site
  • Contact Alcon Call Center at 1-888-451-3937
    Fort Worth, Texas 76134, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2007
First posted
Dec 21, 2007
Start
Dec 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Dec 3, 2012
Last update
Dec 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00579020
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Dec 21, 2007
Start date
Dec 2007
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Dec 5, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Moxifloxacin · Dexamethasone phosphate

Start the discussion